Photolysis and UV/H2O2 of diclofenac, sulfamethoxazole, carbamazepine, and trimethoprim: Identification of their major degradation products by ESI-LC-MS and assessment of the toxicity of reaction mixtures by Alharbi, Sultan et al.
University of Wollongong
Research Online
Faculty of Science, Medicine and Health - Papers:
part A Faculty of Science, Medicine and Health
2017
Photolysis and UV/H2O2 of diclofenac,
sulfamethoxazole, carbamazepine, and
trimethoprim: Identification of their major
degradation products by ESI-LC-MS and
assessment of the toxicity of reaction mixtures
Sultan Alharbi
University of Wollongong, skma437@uowmail.edu.au
Jinguo Kang
University of Wollongong, jkang@uow.edu.au
Long D. Nghiem
University of Wollongong, longn@uow.edu.au
Jason P. Van De Merwe
Griffith University
Frederic Leusch
Griffith University
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Alharbi, S. K., Kang, J., Nghiem, L. D., van de Merwe, J. P., Leusch, F. D. L. & Price, W. E. (2017). Photolysis and UV/H2O2 of
diclofenac, sulfamethoxazole, carbamazepine, and trimethoprim: Identification of their major degradation products by ESI-LC-MS
and assessment of the toxicity of reaction mixtures. Process Safety and Environmental Protection, 112 (Part B), 222-234.
See next page for additional authors
Photolysis and UV/H2O2 of diclofenac, sulfamethoxazole,
carbamazepine, and trimethoprim: Identification of their major
degradation products by ESI-LC-MS and assessment of the toxicity of
reaction mixtures
Abstract
The photolysis of diclofenac (DCF), sulfamethoxazole (SMX), carbamazepine (CBZ), and trimethoprim
(TMP) was investigated using a low-pressure (LP) mercury ultraviolet (UV) lamp (254nm) and a
combination of UV with hydrogen peroxide (H2O2). For each experiment, 5mg/L of each pharmaceutical
was prepared in pure water and individually degraded by either UV alone or UV/H2O2. DCF and SMX were
highly susceptible to UV treatment and completely degraded to below their LC-MS detection limit (1μg/L)
after only 8min of UV irradiation. TMP and CBZ were more resistant to UV treatment, with only 58.2 and
25.2% degradation (after 1h UV exposure). The combination of H2O2 addition (up to 0.2g/L) with UV
significantly improved the removal rate of TMP and CBZ up to 91.2 and 99.7% of the initial concentration,
respectively. A number of novel transformation compounds were identified as UV or UV/H2O2 degradation
products using LC-MS. The range and amount of these transformation compounds strongly depended on the
applied treatment conditions. The toxicity of each pharmaceutical solution before and after treatment was also
evaluated and all parent compounds were non-toxic at the tested concentration (i.e. 5mg/L). DCF, in
particular, but also CBZ and SMX, showed an increase in solution toxicity after treatment with UV only,
indicating the presence of photolytic degradation products that are more toxic than the parent compounds.
Treatment with UV/H2O2 reduced the toxicity of all solutions to below the detection limit of the assay.
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Abstract 20 
The photolysis of diclofenac (DCF), sulfamethoxazole (SMX), carbamazepine (CBZ), and 21 
trimethoprim (TMP) was investigated using a low-pressure (LP) mercury ultraviolet (UV) 22 
lamp (254 nm) and a combination of UV with hydrogen peroxide (H2O2). For each 23 
experiment, 5 mg/L of each pharmaceutical was prepared in pure water and individually 24 
degraded by either UV alone or UV/H2O2. DCF and SMX were highly susceptible to UV 25 
treatment and completely degraded to below their LC-MS detection limit (1 µg/L) after only 26 
8 min of UV irradiation. TMP and CBZ were more resistant to UV treatment, with only 58.2 27 
and 25.2% degradation (after 1 h UV exposure). The combination of H2O2 addition (up to 0.2 28 
g/L) with UV significantly improved the removal rate of TMP and CBZ up to 91.2 and 99.7% 29 
of the initial concentration, respectively. A number of novel transformation compounds were 30 
identified as UV or UV/H2O2 degradation products using LC-MS. The range and amount of 31 
these transformation compounds strongly depended on the applied treatment conditions. The 32 
toxicity of each pharmaceutical solution before and after treatment was also evaluated and all 33 
parent compounds were non-toxic at the tested concentration (i.e. 5 mg/L). DCF, in 34 
particular, but also CBZ and SMX, showed an increase in solution toxicity after treatment 35 
with UV only, indicating the presence of photolytic degradation products that are more toxic 36 
than the parent compounds. Treatment with UV/H2O2 reduced the toxicity of all solutions to 37 
below the detection limit of the assay. 38 
Keywords: UV photolysis; UV/H2O2 advanced oxidation process; degradation product 39 
identification; BLT-Screen; Wastewater treatment  40 
  41 
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1. Introduction 42 
The presence and fate of pharmaceutically active compounds (PhACs) in urban wastewater is 43 
of substantial environmental concern due to their widespread occurrence [1]. It has been 44 
repeatedly observed that conventional wastewater treatment is unable to sufficiently eliminate 45 
many PhACs [1-6]. Examples of persistent PhACs include diclofenac (DCF), 46 
sulfamethoxazole (SMX), carbamazepine (CBZ), and trimethoprim (TMP), which are anti-47 
inflammatory, antibiotic, anticonvulsant, and antibiotic drugs, respectively. These compounds 48 
are resistant to conventional water treatment processes, as shown by their global detection in 49 
wastewater treatment plant effluents, surface water and groundwater [1, 3, 7-9]. The presence 50 
of PhACs in surface and drinking waters elicits concerns about both their ecological impact 51 
on aquatic organisms and their potential to adversely affect public health [10]. Aquatic 52 
toxicity, the development and maintenance of antibiotic resistance and endocrine disruption 53 
have all been associated with particular PhAC pollutants [2, 11-14]. For example, the chronic 54 
exposure of bacteria to trace concentrations of antibiotic pharmaceuticals such as TMP and 55 
SMX in the aquatic environment can result in induction of antibacterial resistant genes [15]. 56 
DCF and CBZ were observed to have adverse impacts on rainbow trout (Oncorhynchus 57 
mykiss) and zebrafish, respectively [16-18]. However, research into chronic health impacts of 58 
long term PhACs exposure to humans and the environment has not yet reached its maturity 59 
[19].  60 
Advanced oxidation processes (AOPs) have been shown to be a promising technology to 61 
degrade PhACs present in wastewater prior to discharge into the aquatic environment. A 62 
number of AOPs have been investigated such as ozonation [20, 21], Fenton and photo-Fenton 63 
oxidation [22], photolysis and UV/hydrogen peroxide (H2O2) [23], and heterogeneous photo-64 
catalysis [24]. The formation of pharmaceutical degradation products by AOPs has also been 65 
identified as a challenge, as degradation products may be more toxic than the parent 66 
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compounds. Ultraviolet (UV) light irradiation is a widely used process for disinfection of 67 
drinking water [25], and is a promising process for wastewater purification. The photolytic 68 
reaction mechanism is especially complicated as it may involve a number of different 69 
reaction pathways forming many unknown degradation products. Some  photolytic 70 
degradation products of UV treatment may be more toxic than, or at least as toxic as, their 71 
parent compounds [26]. Many common pharmaceutical compounds are susceptible to 72 
degradation by UV at typical disinfection doses [27, 28]. Experiments have shown that DCF 73 
and SMX are well degraded during UV photolysis and UV/H2O2 treatment [29]. On the other 74 
hand, low rates of removal of CBZ have been observed during photo-degradation [30, 31]. 75 
Whilst its degradation rates are low, the major photolytic degradation products formed, 76 
acridine and acridone, are known to be more toxic than their parent compound, possessing 77 
considerable mutagenic and carcinogenic characteristics [26, 32-34]. The combination of UV 78 
with H2O2 significantly improves the removal of resistant pharmaceuticals compared to UV 79 
alone. The hydroxyl radical (
•
OH) is produced during UV/H2O2 as a result of UV photolysis 80 
of H2O2. 
•
OH, which is strong oxidant, can attack a wide range of organic compounds 81 
causing degradation through a series of steps including hydroxylation and dehydrogenation 82 
[23]. 83 
Photo-degradation reactions can occur directly and indirectly [35, 36]. In direct photo-84 
degradation, a compound absorbing radiation can become unstable and consequently decay, 85 
whereas the indirect pathway involves naturally occurring compounds that produce strong 86 
reactive species (such as singlet oxygen, and/or hydroxyl radicals) that then react with 87 
organic compounds. The photolytic degradation products formed may have molecular 88 
weights lower than their parent compounds [30, 37, 38]. Conversely the detected photolytic 89 
degradation products could be observed with slightly higher molecular weights than their 90 
parent compounds, as a result of radical additions rather than direct photolysis [30, 37]. 91 
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Additionally, photolytic degradation products with significantly larger molecular weights, 92 
such as the formation of dimers, can be produced during irradiation through 93 
photopolymerization [39, 40]. In general, the degradation products formed tend to display 94 
different reactivity within the system to those of their parent compounds. However, research 95 
conducted into the identification of these degradation products is limited. Consequently, 96 
further investigation is required to fully elucidate the UV photolysis and UV/H2O2 97 
degradation of PhACs. 98 
The overarching purpose of our work was to comprehensively investigate the degradation of 99 
four pharmaceuticals, namely, diclofenac (DCF), sulfamethoxazole (SMX), carbamazepine 100 
(CBZ), and trimethoprim (TMP), by UV photolysis and UV/H2O2 advanced oxidation 101 
process. The scope of this current paper was to analyse the range of degradation products 102 
formed and identify previously unreported degradation products. Additionally, to confirm the 103 
structure, where possible, of compounds previously reported using m/z ratio and mass 104 
fragmentation. This also involved investigating the rate of degradation of the four (parent) 105 
pharmaceuticals and the evolution of major degradation products. In addition, the toxicity of 106 
the treated solutions was tested in a typical bacteria toxicity assay in order to evaluate the 107 
relative toxicity of the mixture of degradation products compared to their parent compounds.    108 
2. Materials and Methods 109 
2.1. Materials and chemicals  110 
Four pharmaceuticals were selected for investigation in this study: diclofenac (DCF), 111 
sulfamethoxazole (SMX), carbamazepine (CBZ), and trimethoprim (TMP) (Fig. 1). The 112 
pharmaceuticals were of analytical grade and purchased from Sigma-Aldrich (Castle Hill, 113 
Australia). All other chemicals (including H2O2) and solvents used in this study were of 114 
analytical or high performance liquid chromatography (HPLC) grade and purchased from 115 
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VWR International (Sydney, Australia). All experiments were carried out using Milli-Q 116 
quality water. 117 
  
  
Figure 1: Molecular structures of the four selected pharmaceuticals. DCF = diclofenac; SMX = 118 
sulfamethoxazole; CBZ = carbamazepine; TMP = trimethoprim. 119 
2.2. UV system 120 
Batch experiments of UV irradiation and UV/H2O2 were carried out in a 0.4 L laboratory-121 
scale UV oxidation system supplied by Ace Glass (Vineland, NJ, USA) that consisted of a 122 
reactor and a low pressure mercury lamp (LP-UV). The low-pressure mercury lamp had a 123 
length of 27 cm, a total UV energy output of 83 W and UV intensity of 1.04 W/cm
2
. It 124 
emitted UV light at a principal wavelength of 254 nm. The UV light was located in the 125 
middle of the reactor, and the solution surrounded the light during the experiments to provide 126 
uniform exposure. A magnetic stirrer was continuously used to provide good mixing of the 127 
reaction solutions during the photolytic reaction (Fig. 2). Further description of the UV 128 
system is available elsewhere [41]. 129 
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 130 
Figure 2: Schematic diagram of UV system used in this study.  131 
The system was connected to a chiller to maintain the temperature at 20ºC. The solution 132 
temperature before and immediately after UV exposure deviated from the set point by 1 to 133 
5ºC depending on the exposure time. Therefore, the solution temperature can be taken as 23 ± 134 
2ºC regardless of the exposure time. It should be noted that the exposure of the solution to the 135 
UV light and the amount of energy absorbed by the compounds is specific to the 136 
configuration of the system. The kinetics of degradation and transformation kinetics are thus 137 
also configuration and system dependent.  138 
2.3 Experimental protocol  139 
Stock solutions containing 5 g/L of DCF, SMX, CBZ, and TMP were prepared using pure 140 
methanol. These were stored in amber bottles and kept in a freezer at -18ºC prior to use. For 141 
LC-MS analysis, calibration standards at concentrations of 1, 10, 50, 100, and 200 µg/L for 142 
each pharmaceutical were freshly prepared from the stocks. 143 
For each UV experiment, 5 mg/L of each target compound were prepared in Milli-Q water 144 
and 0.3 L was transferred into the UV reactor. Although, these pharmaceuticals are frequently 145 
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detected in wastewater at concentrations of up to several µg/L, a relatively high concentration 146 
(i.e. 5 mg/L) was used to facilitate detection and identification of potential degradation 147 
products. The initial concentration of the selected pharmaceuticals is not expected to play any 148 
major role in the photolytic reaction pathways. The UV light was switched on until the 149 
desired exposure time was achieved. After the reaction took place 1 mL of the sample was 150 
transferred to a LC-MS vial to be analysed. The remaining sample was stored in an amber 151 
glass bottle for solid phase extraction (SPE). For each UV/H2O2 experiment, the desired H2O2 152 
concentration was directly added to the solution prior switching the UV light on.  153 
The sensitivity of the analysis for the identification of the degradation products was increased 154 
by pre-concentrating with SPE cartridges. Sep-Pak cartridges (C18 6 cc Vac; 500 mg sorbent 155 
per cartridge; 55-105 µm particle size) were purchased from Waters (Rydalmere, NSW, 156 
Australia). The cartridges were first pre-conditioned with a 7 mL dichloromethane and 157 
methanol mixture (1:1 v/v), 7 mL of methanol, followed by 7 mL of Milli-Q water. Then, the 158 
samples were loaded onto the cartridges at a flow rate of 1–5 mL/min. The extracted 159 
degradation products were eluted from the cartridge using 5 mL of methanol at a flow rate of 160 
1–5 mL/min.   161 
 2.4. Analytical methods 162 
A liquid chromatography – electrospray ionisation - mass spectrometer (LC-ESI-MS) 163 
(Shimadzu single quadrupole LC-MS 2020) was used to identify parent compounds and 164 
degradation products with a variety of masses and polarities. To optimise the LC-MS 165 
parameters a number of preliminary experiments were conducted. The detected degradation 166 
product peaks were classified as large (L), medium (M), or small (S) based on the 167 
chromatographic peak abundance. Those with a signal-to-noise (S/N) ratio of < 10 were 168 
eliminated from further analysis. 169 
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Compounds were separated using a Kinetex® PFP 100A column (100 mm × 3 mm, 12.6 µm) 170 
and a binary gradient made of (A) 0.1% formic acid in Milli-Q water, and (B) acetonitrile at a 171 
flow rate of 500 µL/min. The injection volume was 20 µL. The gradient used for SMX, CBZ, 172 
and TMP was (%B): 0.01 min (5%), 5 min (10%), 20 min (45%), 23 min (90%), 28.1 min 173 
(90%), 29 min (10%), 33 min (10%), and 35.01 min controller stop. The column temperature 174 
was maintained at 31°C. For DCF the gradient was (%B): 0.01 min (10%), 5 min (20%), 15 175 
min (30%), 23 min (30%), 28.1 min (45%), 33 min (45%), 40 min (90%), 41.01 min (10%), 176 
43.01 min (10%), and 45.01 min controller stop. Mass spectrometric data were collected in 177 
both positive and negative ion mode, from m/z 150 to 550. The detected degradation products 178 
were then confirmed using selected scan mode. All of the detector parameters were held 179 
constant during analysis. These include interface temperature (350ºC), nebulizing gas flow 180 
(1.5 L/min), dry gas flow (3 L/min), DL temperature (250ºC) and heat block temperature 181 
(200ºC).  182 
2.5. Toxicity assessment 183 
The toxicity of sample solutions before and after the treatment was evaluated using the 184 
bacterial luminescence toxicity screen (BLT-Screen) [42] .The samples were treated using 185 
UV only or UV/H2O2 for the desired UV exposure time and H2O2 amount. Then, the treated 186 
and untreated solutions were extracted using SPE cartridges (as described above) and eluted 187 
using 3 mL methanol, for an SPE enrichment factor of 100. A detailed description of the 188 
BLT-Screen method is available elsewhere [42], but in brief, the samples were serially 189 
diluted in a phosphate buffered saline medium and an aliquot of the naturally luminescent 190 
bacteria, Photobacterium leiognathi, was added to each dilution. Following 30 min of 191 
exposure, the luminescence in each dilution was measured on a Fluostar Omega plate reader 192 
(BMG Labtech, Germany) and the inhibition of luminescence was calculated relative to a 193 
negative control. The concentration of the sample required to inhibit bacterial luminescence 194 
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by 20% (IC20) was then calculated for each sample by linear regression of the % inhibition vs. 195 
relative enrichment factor [42] within the linear range of the concentration-effect curve (from 196 
0 to 40% inhibition). All results are presented as a relative toxicity unit (rTU), the reciprocal 197 
of the IC20. 198 
 199 
3. Result and discussion 200 
3.1. Effect of UV and UV/H2O2  201 
Experiments to determine the reactivity of 5 mg/L solutions of DCF, SMX, CBZ and TMP 202 
toward low pressure mercury UV light were performed over different UV exposure times. 203 
DCF and SMX were effectively degraded by UV exposure, with >90% reduction after 3 min 204 
and complete removal (to below their LC-MS detection limit of 1 µg/L) within 8 min (Fig. 3). 205 
Therefore, it can be concluded that DCF and SMX were readily photodegradable by UV 206 
photolysis and that a combination of UV with H2O2 was not required for more efficient 207 
degradation. By contrast, CBZ and TMP were quite resistant toward UV photolysis (Fig. 4) 208 
and a combination of UV with H2O2 was essential in order to improve the removal efficiency 209 
of CBZ and TMP (Fig. 4).  210 
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 211 
Figure 3: Effect of UV irradiation on degradation of  DCF and SMX (C0 = 5 mg/L). 212 
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 214 
Figure 4: Effect of H2O2 concentration during UV irradiation on degradation of  CBZ and TMP 215 
(C0 = 5 mg/L). 216 
 217 
The degradation of CBZ by UV photolysis and UV/ H2O2 advanced oxidation was 218 
investigated under a wide range of UV exposure times and H2O2 concentrations. CBZ 219 
removal by UV photolysis only (i.e. 0 g/L H2O2) was low, and only 25.2% of the initial CBZ 220 
concentration was lost after 60 min of UV exposure (Fig. 4). As expected, a much higher 221 
degradation rate for CBZ was achieved when the H2O2 concentration was increased. Adding 222 
H2O2 prior to UV irradiation produces highly reactive and nonselective hydroxyl radicals 223 
causing further degradation of the target compound [23]. The addition of 0.2 g/L of H2O2 224 
prior UV exposure removed about 95% of the initial CBZ concentration after 30 min of 225 
irradiation with almost complete (99.7%) removal observed after 1 hour of UV exposure, 226 
demonstrating the effectiveness of the H2O2 addition for CBZ removal. Clearly, an increasing 227 
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H2O2 dose together with UV irradiation can achieve higher removal efficiency in a shorter 228 
UV exposure time, compared with a low H2O2 dose.  229 
The photodegradation of TMP by UV light and UV/H2O2 advanced oxidation was also 230 
evaluated under a wide range of UV exposure time and H2O2 concentrations. TMP was found 231 
to be moderately reactive towards UV photolysis with up to 71.2% of the initial TMP 232 
concentration lost after 90 min of UV exposure alone (Fig. 4). Similar to CBZ, increasing the 233 
concentration of H2O2 significantly improved the rate of TMP degradation. However, TMP 234 
required a longer exposure time (90 min) compared to CBZ (60 min) during UV with 0.2 g/L 235 
H2O2 in order to achieve over 97.4% removal of the initial TMP concentration, and TMP was 236 
not completely removed after 90 min of UV irradiation even with the addition of 0.2 g/L 237 
H2O2. Complete removal of TMP may be achieved by further increasing the irradiation time 238 
and/or the H2O2 concentration. Therefore, the CBZ and TMP degradation rate were 239 
controlled by the amount of the added hydrogen peroxide before UV exposure producing free 240 
radicals.   Overall, after a sufficient UV exposure time (i.e. 60 min for CBZ and 90 min for 241 
TMP), there was no significant difference between the removal efficiency when H2O2 242 
concentrations of 0.12 and 0.2 g/L were present. Therefore, a cost trade-off may exist 243 
between H2O2 chemical consumption and UV exposure time for effective removal. 244 
3.2. Formation of degradation products 245 
3.2.1 Diclofenac 246 
A total of fifteen photolytic degradation products were detected during UV photolysis of 247 
DCF,. Eight of these (compounds # 7 – 12, 14, and 15) are reported here for the first time to 248 
the best of our knowledge (Table 1). The DCF degradation products were eluted through the 249 
LC-MS column at different retention times (RT) based on their hydrophobicity; all were at 250 
lower RT than DCF (Fig. 5). All peaks presented in the LC chromatogram had their 251 
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molecular weight determined in the MS spectra. The majority of these degradation products 252 
were detected in both negative and positive scan mode, which was useful to confirm their 253 
correct molecular weight.  254 
 255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
Figure 5: Typical LC-MS chromatogram for DCF and its major UV photolytic degradation 268 
products in negative scan mode (3 min UV exposure).   269 
A number of the newly detected photolytic DCF degradation products #11, 12, 14, and 15 270 
were proposed to be formed via dimerization. The formation of other dimer DCF degradation 271 
products during UV irradiation of DCF has been reported previously elsewhere [40, 43]. 272 
The irradiation of DCF using LP-UV mercury lamp leads to sequential elimination of the 273 
chlorine substituents within the DCF structure, followed by ring closure to form carbazole-1- 274 
acetic acid, which is considered the primary photolytic degradation product. The primary 275 
photolytic DCF compound #1 has been previously identified in a number of studies [43-46]. 276 
Additionally, Compounds # 2, 3, 4, 5, and 6 have also been reported as photolytic DCF  277 
degradation products [43]. Compound #13 has also been previously reported during DCF 278 
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photolysis elsewhere [47]. The fragmentation patterns obtained by MS of compound #1 have 279 
confirmed the previously reported structures in the literature: its molecular weight was 280 
determined to be 259 amu, with molecular formula C14H10ClNO2. The collision-activated 281 
dissociation of [M─H]─ molecular ion of the main  photolytic degradation product 2-(8-282 
chloro-9H-carbazol-1-yl) acetic acid represented the ions at m/z = 214 and 178, in agreement 283 
with another study [48]. Mass losses from this photolytic degradation product were 284 
accordingly reported to be 44(CO2) and 80 (CO2 and HCl) amu, respectively (Fig. 6).   285 
  
Figure 6: The primary DCF UV photolytic degradation product [43-46]. 286 
   287 
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288 
Figure 7: Evolution of main photolytic degradation products formed during degradation of 5 289 
mg/L DCF by UV as determined by LC-MS. 290 
 291 
Table 1: The degradation products produced from UV photolysis of DCF as identified by LC-292 
MS. 293 
Compound 
Retention time 
(min) 
Molecular ion (m/z) Molecular mass 
(g/mol) 
Peak 
Abundance* [M − H]− [M + H]
+ 
DCF 31.42 294.1 296 295  
1 28.83 258.1 - 259 L 
2 26.95 479.2 481.2 480 M 
3 16.24 240.2 242 241 M 
4 27.24 493.1 495.1 494 M 
5 13.71 523.1 525.1 524           M 
6 11.55 254.1 256.1 255 M 
7 9.40 226.1 - 227 S 
8 9.92 256.1 258.1 257 S 
9 11.90 284.1 286.1 285 S 
10 14.00 212.2 - 213 S 
11 19.05 465.1 467.2 466            S 
12 21.02 493.2 495.2 494 M 
13 22.03 224.2 - 225 S 
14 25.37 479.2 - 480 S 
15 30.80 511.1 513.2 512 S 
*An indication for degradation products abundance (i.e. Large (L), Medium (M), and Small (S)). 294 
Peaks with S/N ratio of < 10 were ignored.  295 
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The evolution of DCF and its major photolytic degradation products was observed during UV 296 
photolysis (Fig. 7). The DCF began to quickly degrade as soon as the UV light was activated 297 
and its major degradation products were produced. Compound #1 reached its highest 298 
concentration after 2 min of exposing the DCF solution to UV. About 40% of the 5 mg/L 299 
DCF concentration was converted to compound #1. Once the DCF was almost completely 300 
consumed, the concentration of compound #1 dramatically decreased and it was completely 301 
removed after 8 min. Interestingly, compound #1 and 6 had similar trends, which could 302 
indicate that these degradation products were formed directly from DCF whereas, the other 303 
degradation products were produced via other pathways. The other four detected degradation 304 
products were not present in the first minute of UV exposure time. They began to form after 305 
1.5 - 2 min and were still detected close to their original concentrations, even after 10 min of 306 
UV exposure, despite their relatively low concentration compared with compound #1. 307 
Therefore, these secondary degradation products, which contain some dimers, seemed to be 308 
highly resistant toward UV photolysis.    309 
3.2.2 Sulfamethoxazole 310 
The UV photolysis of SMX in pure water generated twelve photolytic degradation products 311 
(Table 2). The majority of these degradation products (compounds #3 –12) were reported as 312 
SMX UV photolytic degradation products for the first time in this study. Compounds #1 and 313 
2 have been previously reported elsewhere [49, 50] (Fig. 8). Similar to DCF degradation 314 
products, the detected SMX photolytic degradation products were eluted through the LC-MS 315 
column at different retention times based on their hydrophobicity. All the photolytic SMX 316 
degradation products were formed at low concentrations, except compound #1, which was 317 
considered to be the primary photolytic SMX degradation product.  318 
18 
 
Table 2: The degradation products produced from UV photolysis of SMX as identified by LC-319 
MS. 320 
Compound 
Retention time 
(min) 
Molecular ion (m/z) Molecular mass 
(g/mol) 
Peak 
Abundance* [M − H]− [M + H]
+ 
SMX 10.30 - 254.1 253  
1 2.91 - 254.1 253 L 
2 1.96 - 99 98 S 
3 5.00 - 296.1 295 S 
4 10.00 266.1 - 267 S 
5 13.43 266.1 - 267 M 
6 11.18 258.2 260.1 259 S 
7 12.50 423.1 - 424 S 
8 15.02 282.1 284.2 283 S 
9 17.62 282.2 284.1 283 S 
10 19.70 - 284.2 283 S 
11 21.00 346.1 - 347 S 
12 22.38 282.2 284.2 283 S 
*An indication for degradation products abundance (i.e. Large (L), Medium (M), and Small (S)). 321 
Peaks with S/N ratio of < 10 were ignored. 322 
The UV photolysis of SMX in aqueous solution undergoes several reaction pathways, the 323 
most predominant involving cleavage of the nitrogen-oxygen bond and rearranging the 324 
isoxazole ring to form a five membered oxazole ring [49]. This compound is 4-amino-N-(5-325 
methyloxazol-2-yl) benzenesulfonamide, which has been previously proposed elsewhere 326 
[49]. Furthermore, it has been reported that the hydroxyl radical may be produced during  UV 327 
photolysis without any photochemical source [30]. This may contribute to the hydroxylation 328 
of SMX mainly on the benzene ring representing another photolytic pathway. Additionally, 329 
compound #1 may undergo hydroxylation similarly to the parent compound, SMX. The 330 
primary SMX photolytic degradation product, compound #1, eluted at 2.91 min on the 331 
reverse-phase LC-MS. In the ESI-MS spectrum a molecular ion at m/z = 254 in positive scan 332 
mode was detected. Therefore, its molecular weight was determined to be 253 amu, with 333 
molecular formula (C10H11N3O3S). The collision-activated dissociation of [M + H]
+
 334 
molecular ion of the primary SMX UV photolytic degradation product represented ions at 335 
m/z = 156, in agreement with a previous study [50]. Mass loss from the [M + H]
+  
was 336 
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reported to be 98 amu, as a result of a cleavage in the sulfur-nitrogen bond within the 337 
structure of compound #1 (Fig. 8).  338 
                                      339 
Figure 8: Major SMX UV photolytic degradation products [49, 50]. 340 
 341 
342 
Figure 9: Evolution of the main degradation product formed during degradation of 5 mg/L 343 
SMX by only UV as determined by LC-MS. 344 
The degradation of SMX and formation of its major photolytic degradation products was 345 
determined during UV photolysis (Fig. 9). SMX had only one major degradation product 346 
whilst all the other degradation products were formed at low concentrations. SMX began to 347 
sharply degrade as soon as it was exposed to UV, leading to the formation of SMX major 348 
photolytic degradation product, compound #1. This compound reached its maximum 349 
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concentration after 1.5 - 2 min of UV exposure time. Once the majority of SMX was 350 
degraded (3 min), compound #1 began to gradually degrade. SMX was removed to below its 351 
LC-MS detection limit (1 µg/L) at 8 min of UV exposure time. A near complete removal of 352 
compound #1 was achieved after 10 min of UV exposure. Therefore, UV photolysis under 353 
these conditions was capable of removing SMX and its major degradation products to below 354 
their LC-MS detection limit.     355 
3.2.3 Carbamazepine 356 
The UV photolysis and UV/H2O2 of 5 mg/L CBZ in pure water produced more than eighteen 357 
CBZ degradation products. Eight of these degradation products (compounds #3, 9, 12, 13, 14, 358 
15, 17, and 18) are reported for the first time in this study (Table 3). The detected degradation 359 
products were eluted through the LC-MS column at different retention times prior to 360 
introducing them to MS for m/z determination. The concentration of CBZ degradation 361 
products was dependent on the type of irradiation applied (e.g. UV only and UV/H2O2 362 
amount). Firstly, a number of degradation products were formed at detectable concentrations 363 
during both UV only and also in combination of UV with varying amounts of H2O2 (i.e #5, 6, 364 
10, 14, 15 and 16). Compounds #5, 6, 10, 14, 15 and 16 eluted at consistent retention times 365 
during all experiments. Additionally, the fragmentation patterns of compounds #5, 6, 10, and 366 
15 also confirmed the formation of these degradation products during different treatment 367 
conditions. Markedly, the different amount of H2O2 played an important role in the evolution 368 
of different CBZ degradation products. For example, UV only and the combination of UV 369 
with 0.01 and 0.04 g/L of H2O2 produced  degradation products #1, 2, 8, 11, and 12 (MW 370 
179, 270, 222, 195, and 211 amu, respectively). Alternatively, three degradation products (#4, 371 
7, and 9; MW 266, 252, and 268 amu, respectively) were detected only during the 372 
combination of UV with every amount of hydrogen peroxide.  Lastly, UV with 0.04 g H2O2/L 373 
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or higher, resulted in the detection of compounds #3 and 13 only (MW 298 and 273 amu, 374 
respectively).  375 
Evidently, the applied oxidation process (i.e.  UV, UV with different H2O2 doses) plays an 376 
important role in the formation of particular degradation products. All of the identified 377 
degradation products were formed at only low concentrations during the experiments. For 378 
UV only, just 25.2% of 5 mg/L CBZ was degraded after 60 min of UV exposure, and only 379 
low concentrations of degradation products were measured. When combined with high H2O2 380 
amounts, UV/H2O2 could be used to simultaneously degrade both the CBZ and its 381 
degradation products. Therefore, the concentrations of degradation products formed during 382 
UV/H2O2 were significantly lower than during UV only.  383 
 384 
Table 3: The degradation products produced from UV photolysis and UV/H2O2 of CBZ as 385 
identified by LC-MS. 386 
Compound 
Retention 
time 
(min) 
Molecular ion (m/z) Molecular 
Mass 
(g/mol) 
Type of irradiation 
Peak 
Abundance* [M − H]− [M + H]
+ 
UV 
only 
UV/H2O2 (g/L) 
0.01 0.04 0.12 0.2 
CBZ 16.00 - 237.1 236       
1 4.00 - 180.2 179 √ √ √   L 
2 10.71 - 271.2 270 √ √ √   S 
3 10.93 - 299.2 298   √ √ √ S 
4 11.53 265.1 267.1 266  √ √ √ √ S 
5 12.10 - 251.1 250 √ √ √ √ √ S 
6 12.30 267.1 269.1 268 √ √ √ √ √ S 
7 12.56 251.2 253.2 252  √ √ √ √ S 
8 12.79 - 223.1 222 √ √ √   M 
9 13.06 - 269.2 268  √ √ √ √ S 
10 13.62 251.2 253.2 252 √ √ √ √ √ S 
11 13.83 - 196.1 195 √ √ √   M 
12 14.72 210.2 212.2 211 √ √ √   S 
13 16.09 272.2 - 273   √ √ √ S 
14 18.53 242.2 244.2 243 √ √ √ √ √ S 
15 19.51 240.2 242.2 241 √ √ √ √ √ S 
16 21.35 - 226.1 225 √ √ √ √ √ S 
17 22.15 256.2 258.2 257 √ √ √ √  S 
18 22.84 - 194.2 193 √     S 
*An indication for degradation products abundance (i.e. Large (L), Medium (M), and Small (S)). 387 
Peaks with S/N ratio of < 10 were ignored. 388 
 389 
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A number of studies have reported some of the CBZ degradation products under a wide range 390 
of reaction conditions [32-34, 51-53].  UV photolysis of CBZ is via two different reaction 391 
pathways [33], the majority of CBZ  UV photolytic degradation products are produced 392 
through a dominant pathway of ring shrinkage. This process would firstly form 9-393 
formylacridine-10(9H)-carboxamide (Compound #10) by hydroxylation at one position on 394 
the non-aromatic double bond of CBZ [33]. In this study, there were two different possible 395 
ways in which compound #10 may progress to form other degradation products. Firstly, 396 
hydroxylation and detaching of the CONH2 lateral chain may have formed compounds #11 397 
and #16. Secondly, the carboxyaldehyde group and CONH2 lateral chain may have both 398 
detached and produced compound #1 [33]. For UV/H2O2, UV exposure to a solution 399 
containing H2O2 would generate 
•
OH which would form compound #7 and drive the 400 
degradation process [23] (Fig. 10).  401 
The fragmentation patterns obtained by MS of compound #10 in this study confirm the 402 
previously elucidated structure in the literature [33]. The collision-activated dissociation of 403 
[M+H]
+
 molecular ion of compound #10 produced ions at m/z = 210 and 180. Mass losses 404 
from the molecular ion were reported to be 43(-HNCO) and 73(-HNCO and –H2CO) amu, 405 
respectively (Fig. 10). The collision-activated dissociation of [M+H]
+
 molecular ion of 406 
compound #1, which was the major CBZ degradation product caused by  UV photolysis, 407 
produced ions at m/z = 152, which is consistent with other literature [32]. Mass losses from 408 
the molecular ion were reported to be 28 amu. The collision-activated dissociation of [M+H]
+
 409 
molecular ion of the CBZ UV photolytic degradation product (compound #11) produced ions 410 
at m/z = 167, in agreement with a previous study [33]. Mass losses from the molecular ion 411 
were reported to be 29 amu. 412 
 413 
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         414 
                                                                      415 
 416 
                                                        417 
Figure 10: Major CBZ UV and UV/H2O2 degradation products [23, 33].   418 
3.2.4 Trimethoprim 419 
The  UV photolysis and UV/H2O2 of 5 mg/L TMP in Milli-Q water produced more than 11 420 
TMP degradation products, including five major ones (Table 4). Three TMP degradation 421 
products (#5, 7 and 11) are reported for the first time, including compound #5, which was a 422 
major degradation product found during UV with 0.04, 0.12, and 0.2 g/L of H2O2. Similar to 423 
CBZ degradation products, the formation of a particular TMP degradation product was 424 
dependent on the type of irradiation applied (e.g. UV only and UV/H2O2 amount). The 425 
identified TMP degradation products formed during UV photolysis could be categorised 426 
based on the applied conditions (i.e. H2O2 amount). Treatment with UV and 0.04, 0.12, and 427 
0.2 g/L H2O2 resulted in detection of the majority of TMP degradation products (i.e. #3, 4, 5, 428 
7, 10, and 11). On the other hand, the degradation products reported during both UV only and 429 
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also when combining UV with a low level (0.01 g/L) of H2O2 (i.e #1, 2, and 6) were only 430 
detected at these conditions. At the higher H2O2 amounts, compounds #1, 2, and 6 were not 431 
detected and therefore may have undergone further degradation. Alternatively, TMP 432 
degradation products #8 and 9, with the same molecular weight (i.e. 322 amu), were detected 433 
during UV only and UV with every H2O2 amount used except 0.2 g/L. Remarkably, four 434 
isomers at m/z = 323 were found, which was consistent with a previous study under different 435 
conditions [54]. Additionally, there were a number of very small peaks that had signal-to 436 
noise ratio less than 10 and did not meet the criteria for further analysis.    437 
Table 4: The degradation products produced from UV photolysis and UV/H2O2 of TMP as 438 
identified by LC-MS. 439 
Compound 
Retention 
time 
(min) 
Molecular ion (m/z) Molecular 
Mass 
(g/mol) 
Type of irradiation 
Peak 
Abundance* [M − H]− [M + H]
+ 
UV 
only 
UV/H2O2 (g/L) 
0.01 0.04 0.12 0.2 
TMP 12.60 - 291 290       
1 13.87 - 305.2 304 √ √    L 
2 9.20 - 307.2 306 √ √    L 
3 10.20 - 323.2 322   √ √ √ L 
4 10.40 - 323.2 322   √ √ √ L 
5 11.28 - 321.2 320   √ √ √ L 
6 8.46 - 295.2 294 √ √    S 
7 9.55 351 353.2 352   √ √ √ M 
8 13.24 - 323.2 322 √ √ √ √  S 
9 15.75 - 323.2 322 √ √ √ √  S 
10 16.41 - 307.1 306   √ √ √ S 
11 20.08 - 275.2 274   √ √ √ S 
*An indication for degradation products abundance (i.e. Large (L), Medium (M), and Small (S)). 440 
Peaks with S/N ratio of < 10 were ignored. 441 
Hydroxylation and carbonylation are thought to be the most dominant pathways during UV 442 
and UV/H2O2, by which the hydroxyl groups could be connected to either rings of the TMP 443 
molecule [55]. Additionally, it has been reported that the UV photolysis of TMP would 444 
include hydroxylation, demethylation, and cleavage of the TMP parent structure [54]. For 445 
instance, compounds #2, 3, 4, 8, 9, and 10 showed addition of 16 or 32 amu to the TMP 446 
molecular weight. Carbonylation may occur at the methylene bond, for example, compounds 447 
#1 and 5. Compounds #1 and 2, which were found to be the primary TMP degradation 448 
products formed by  UV photolysis, have been reported elsewhere during UV photolysis 449 
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under different conditions [54] (Fig. 11). Moreover, compounds #1, 2, 3, and 4 have also 450 
been reported during UV/H2O2 of TMP in artificial urine solutions [55]. However, 451 
compounds #1 and 2 were not detected during UV with 0.04, 0.12, and 0.2g H2O2/L in Milli-452 
Q water. This may indicate that the addition of high amounts of H2O2 may cause reaction 453 
with TMP prior to significant UV exposure. The detection of compound #5, which had one 454 
additional oxygen atom to compound #1, may confirm the hydroxylation of compound #1 455 
(Fig. 12).  456 
The fragmentation patterns obtained by MS of the major TMP degradation products have 457 
confirmed the previously reported degradation products in the literature. The collision-458 
activated dissociation of [M+H]
+
 molecular ion of compound #1 produced ions at m/z = 289,  459 
275, 259, 244, and 233. Mass losses from the molecular ion were found to be 16, 30, 46, 61, 460 
and 72 amu, respectively, with the first two fragments in agreement with another study [54]. 461 
The collision-activated dissociation of [M+H]
+
 molecular ion of compound #2 produced ions 462 
at m/z = 289,  274, 259, 243, and 231. Mass losses from the molecular ion were accordingly 463 
reported to be 18, 33, 48, 64, and 76 amu, respectively, in agreement with another study [54]. 464 
The collision-activated dissociation of [M+H]
+
 molecular ion of compound #3 and 4 465 
produced ions at m/z 181. The collision-activated dissociation of [M+H]
+
 molecular ion of 466 
compound #5 produced ions at m/z 303 and 273. Mass losses from the molecular ion were 467 
found to be 18 and 48 amu, respectively.  468 
 469 
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                          470 
                          471 
Figure 11: Major TMP  UV and UV/H2O2 degradation products [54].  472 
             473 
 474 
Figure 12: Proposed structure of compound #5.  475 
The evolution of the main TMP degradation products during UV photolysis and UV with a 476 
different concentration of H2O2 was determined (Fig. 13). During UV photolysis, the major 477 
TMP degradation products were compounds #1 and 2, which were formed as TMP was 478 
gradually degraded (Fig. 13A). Approximately 75% of 5 mg/L TMP was removed after 90 479 
min of UV exposure. However, the photolytic degradation products did not show any 480 
decrease in their concentrations, which may indicate their persistence to UV photolysis. With 481 
a combination of UV and H2O2 the degradation products (compounds #3, 4 and 5) displayed 482 
different evolutionary behaviour at each H2O2 concentration (Fig. 13B-D). The three 483 
degradation products were produced at similar concentrations for all H2O2 amounts used, 484 
however, the observed irradiation time varied significantly for each. The irradiation times to 485 
reach the highest concentration of degradation products were 60, 30 and 20 min, for H2O2 486 
amounts of 0.04, 0.12 and 0.2 g/L, respectively. This was likely due to the faster TMP 487 
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degradation rate as a result of the higher H2O2 amount present in the solution during UV 488 
exposure. Once the majority of TMP had been degraded, the concentrations of the 489 
degradation products reduced with further irradiation time. Therefore, within 90 min 490 
irradiation time, compounds #3, 4 and 5 were highly susceptible to the oxidation process 491 
used. Results indicate that the highest H2O2 amount could achieve the highest removal of 492 
TMP, and also the degradation products showed the lowest final concentration. 493 
 494 
495 
Figure 13: Evolution of main  degradation products formed during degradation of 5 mg/L TMP 496 
by UV exposure with (A) 0, (B) 0.04 2, (C) 0.12, and (D) 0.2 g/L of H2O2. 497 
 498 
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3.3. Photolytic solution toxicity  503 
The toxicity of the four pharmaceuticals and their degradation product mixtures during UV 504 
photolysis and UV/H2O2 were evaluated (Table 5). None of the tested parent compounds 505 
were toxic in the BLT-Screen at the concentration tested (all <0.6 rTU at 5 mg/L), but most 506 
(DCF, CBZ and SMX) showed an increased level of toxicity after UV treatment, most likely 507 
as a result of more toxic photolytic degradation products in the solution. The toxicity of the 508 
DCF solution increased dramatically from <0.6 to 6.7-7.2 rTU after 3, 5, and 10 min of UV 509 
exposure, during a time window when the sample contained six degradation products at 510 
relatively high concentrations (Fig. 7). Applying a high H2O2 dose (i.e. 0.12 g/L) and a long 511 
UV exposure time (i.e. 20 min) to DCF effectively produced final degradation products with 512 
toxicity similar to the original solution (<0.6 rTU). The toxicity of the CBZ solution was 513 
increased to 1.7 rTU after 60 min of UV exposure. This CBZ solution contained 3.74 mg/L of 514 
CBZ and a number of photolytic degradation products with a relatively predominant 515 
abundance of compound #1. The combination of UV with 0.12 g/L of H2O2 for the removal 516 
of CBZ reduced the solution toxicity again to below the detection limit of the assay (<0.6 517 
rTU). The SMX solution toxicity showed slightly elevated toxicity (0.7 rTU) after 3 min of 518 
UV exposure compared to below detection limit (<0.6 rTU) for untreated SMX solution. In 519 
contrast, the TMP solution showed no change in toxicity during UV exposure, or when 520 
combined with H2O2 (all <0.6 rTU). Therefore, although UV treatment may lead to the 521 
formation of toxic degradation products for DCF, in particular, but also CBZ and SMX, the 522 
combination with H2O2 effectively degraded them into less toxic degradation products. 523 
 524 
 525 
 526 
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Table 5: The solution toxicity of the parent pharmaceuticals and their degradation products 527 
under different reaction conditions. Toxicity is expressed as relative toxic unit (rTU), calculated 528 
as 1/IC20
 
in the BLT assay. 529 
Pharmaceuticals 
Experimental conditions Toxicity in the 
BLT (rTU) UV exposure time (min) H2O2 amount (g/L) 
 
 
DCF-5mg/L 
0 - <0.6 
3 - 6.7 
5 - 6.7 
10 - 7.2 
20 0.12 <0.6 
 
CBZ-5mg/L 
0 - <0.6 
60 - 1.7 
60 0.12 <0.6 
 
SMX-5mg/L 
0 - <0.6 
3 - 0.7 
3 0.01 <0.6 
 
TMP-5mg/L 
0 - <0.6 
90 - <0.6 
90 0.12 <0.6 
 530 
4. Conclusion  531 
This work provides further insights to the UV photolysis and UV/H2O2 of DCF, SMX, DCF, 532 
and TMP. DCF and SMX were easily degraded to below their LC-MS detection limit (1 533 
µg/L) after only 8 min of exposure to UV photolysis, and there was no need to combine UV 534 
with H2O2 to improve their removal. However, the addition of H2O2 may be essential during 535 
UV photolysis of DCF to avoid the formation of toxic degradation products during UV alone.  536 
CBZ and TMP were quite resistant to UV photolysis, whereas, the combination of UV with 537 
H2O2 significantly improved the removal of CBZ and TMP, with higher H2O2 dose resulting 538 
in better removal. A number of new degradation products have been identified in this study 539 
for all of the four selected pharmaceuticals during UV and UV/H2O2 photolysis. Some of the 540 
identified CBZ and TMP degradation products during UV photolysis were different from 541 
those formed during UV/H2O2. The combined oxidation process using only UV and UV with 542 
different H2O2 plays an important role in the formation of CBZ and TMP degradation 543 
products. Some of the formed degradation product mixtures were more toxic than their parent 544 
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compounds, whereas others did not show any change in toxicity compared with their parents. 545 
This work clearly illustrates the need to conduct both chemical and toxicity analysis in 546 
parallel to provide a more comprehensive assessment of removal mechanisms. Further work 547 
is currently underway to enable a comprehensive identification of new detected degradation 548 
products using their fragmentation ions for structural confirmation.  549 
 550 
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